Jason Mast , 2025-04-30 12:26:00
Contents
Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront.
The immediate payout is more than triple Regulus’ current market cap. Novartis could pay another $900 million depending on whether the drug achieves an unspecified regulatory milestone.
The deal could provide a bit of hope for other investors in small biotechs, who have watched stock prices plummet in recent years and are hoping that larger companies could swoop in and buy them for something close to their original valuations.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
